In a three-day meeting this week, the FDA Oncologic Drugs Advisory Committee will be asked to determine viability of six indications for drugs that target PD-/PD-L1 proteins.
The White House moonshot to accelerate progress in cancer research directs FDA to consolidate its oncology portfolio.
